Pharma ‘Making Progress’ On Medicines Access, But Gaps Remain
A new report says that the 20 major companies in the Access to Medicines Index have made progress in areas like inclusive business models, R&D prioritization and equitable pricing, but not enough is being done to develop new medicines for less profitable diseases or to support flexibilities such as compulsory licensing.
You may also be interested in...
The Medicines Patent Pool has developed a new prioritization framework to identify promising drug candidates for in-licensing, including in the antibiotics area, after its scope was expanded beyond its initial target areas. Later this year it also plans to look at whether its licensing model could be adapted to biologic medicines.
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
A “powerful new vision” for the post-Brexit UK regulatory framework was unveiled at a conference organized by the BioIndustry Association and the medicines regulator, the MHRA.